This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
The Zacks Analyst Blog Highlights Alibaba Group, TotalEnergies, ConocoPhillips, Elevance Health and The Charles Schwab
by Zacks Equity Research
Alibaba Group, TotalEnergies, ConocoPhillips, Elevance Health and The Charles Schwab are part of the Zacks top Analyst Blog.
Top Stock Reports for Alibaba, TotalEnergies, ConocoPhillips & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), TotalEnergies SE (TTE) and ConocoPhillips (COP).
Why Elevance Health (ELV) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Elevance Health (ELV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Elevance Health (ELV) closed at $449.26 in the latest trading session, marking a +0.11% move from the prior day.
Here's Why Investors are Retaining Elevance (ELV) Stock Now
by Zacks Equity Research
Elevance's (ELV) focus on expanding the capabilities of the Carelon platform is likely to position the company for long-term growth.
Elevance Health (ELV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Elevance Health (ELV) closed at $450.15, marking a +1.76% move from the previous day.
Elevance Health (ELV) Stock Moves 0.38%: What You Should Know
by Zacks Equity Research
Elevance Health (ELV) closed the most recent trading day at $459.57, moving +0.38% from the previous trading session.
Medtronic's (MDT) Inceptiv Spinal Cord Stimulator Gets CE Mark
by Zacks Equity Research
Medtronic's (MDT) Inceptiv SCS System is the first Medtronic SCS device to offer a closed-loop feature that senses each person's unique biological signals.
BrainsWay (BWAY) Expands Foothold in Taiwan With Deep TMS
by Zacks Equity Research
The collaboration between BrainsWay (BWAY) and Unison Healthcare Group signifies a coordinated effort to enhance access and awareness of Deep TMS in Taiwan.
LabCorp (LH) Suffers From Lower COVID Test Sales, Macro Woes
by Zacks Equity Research
Labcorp's (LH) Early Development Research Laboratories business continues to be constrained by NHP-related supply-chain issues.
Charles River (CRL) Collaborates With Fondazione Telethon
by Zacks Equity Research
Charles River (CRL) is excited about Fondazione Telethon's collaboration to produce HQ plasmid DNA for the lentivirus used in ex vivo gene therapy developed by Fondazione Telethon.
Elevance Health (ELV) Stock Moves -0.84%: What You Should Know
by Zacks Equity Research
In the latest trading session, Elevance Health (ELV) closed at $456, marking a -0.84% move from the previous day.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) on the expanded global installed base of more than 3,250 Panthers instruments, representing the catalyst for sustained growth.
Veeva Systems (VEEV) to Support Civica Rx Quality Control
by Zacks Equity Research
Veeva Systems' (VEEV) Vault LIMS will streamline internal testing and manufacturing while promoting lead time adherence.
Thermo Fisher (TMO) Launches New Chromosomal Microarray
by Zacks Equity Research
Thermo Fisher's (TMO) CytoScan HD Accel array can save labs weeks or even months by accelerating the time it takes to get findings from cytogenetic research.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) successful integration of the recently-acquired business and raised guidance.
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), led by Invisalign portfolio expansion and raised guidance.
Here's Why You Should Invest in Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are upbeat about Penumbra (PEN) on Strong uptake following the launch of Lightning Flash, which accelerated top-line growth.
Why Is Elevance Health (ELV) Down 3.4% Since Last Earnings Report?
by Zacks Equity Research
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Accenture, Elevance Health, Analog Devices, Monster Beverage and West Pharmaceutical Services
by Zacks Equity Research
Accenture, Elevance Health, Analog Devices, Monster Beverage and West Pharmaceutical Services are part of the Zacks top Analyst Blog.
Top Research Reports for Accenture, Elevance Health & Analog Devices
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Accenture plc (ACN), Elevance Health, Inc. (ELV) and Analog Devices, Inc. (ADI).
Alcon (ALC) Q2 Earnings Surpass Estimates, Margins Increase
by Zacks Equity Research
Alcon (ALC) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Here's Why Elevance Health (ELV) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Asensus Surgical (ASXC) Q2 Loss Widens, Revenues In Line
by Zacks Equity Research
Asensus Surgical (ASXC) reports a significant increase in total surgical procedures completed utilizing the Senhance System.